StreetInsider.com News Articles

BMO Capital on Incyte (INCY): ''989 Updates Provide More Context to ET/MF Opportunity'

Mon, 15 Jun 2026 10:10:54 -0400

BMO Capital analyst Evan David Seigerman reiterated an Underperform rating and $75.00 price target on Incyte (NASDAQ: INCY).

The analyst commented: "'989 Updates Provide More Context to ET/MF Opportunity; Lower efficacy measures for '989 in larger patient groups likely reads incrementally negative to INCY shares, but opportunity still remains for future development. EHA updates for Incyte's mCALR antibody, '989 showed lower complete hematologic responses in ET vs. prior measures (70% vs. 76% at ASH), but speed of responses in ~2 weeks is encouraging for rapid symptom relief. Updated monotherapy MF data similarly shows mild regression for both SVR35 and TSS50, but

Stifel Reiterates Buy Rating on Incyte (INCY)

Mon, 15 Jun 2026 09:24:59 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $123.00 price target on Incyte (NASDAQ: INCY).

The analyst commented, "Incremental P1 INCA033989 (‘989) MF/ET data won’t quiet lingering questions re: directionally-lower activity in nonType-1 (vs. Type-1) patients that increasingly-seems more like a potential biological limitation/consequence of single C-terminus epitope targeting vs. a limitation of dosing (formulation-advantaged DMR-001 also shares near-identical Kd and proliferation inhibition differentials between Type-1/non-Type-1). We believe the implications of this efficacy differential in 2L+ ET is inconsequential given ‘989’s non-Type-1 DCHR/ CHR still outpaces any best-available-therapy outcome (and is further-advantaged via the truncated/FDA-aligned Week-24 endpoint in P3 development).

Mirum and Incyte report positive phase 2 results for FOP treatment

Sun, 14 Jun 2026 16:35:17 -0400

Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) and Incyte Corp. (NASDAQ: INCY) announced positive results from a phase 2 study of zilurgisertib for treating fibrodysplasia ossificans progressiva, a rare genetic disease that causes bone formation in soft tissues.

The PROGRESS study evaluated zilurgisertib in 63 adolescents and adults aged 12 years and older with FOP. Patients received either zilurgisertib 100 mg daily or placebo for 24 weeks, followed by an open-label extension period where all participants received the active treatment.

At 24 weeks, 3.1% of patients receiving zilurgisertib developed new heterotopic ossification lesions compared to 16.7% in the placebo group, representing an 81% reduction.

Mirum and Incyte report positive phase 2 results for FOP treatment

Sun, 14 Jun 2026 16:35:17 -0400

At 24 weeks, 3.1% of patients receiving zilurgisertib developed new heterotopic ossification lesions compared to 16.7% in the placebo group, representing an 81% reduction.

Mirum and Incyte report positive phase 2 results for FOP treatment

Sun, 14 Jun 2026 16:35:17 -0400

At 24 weeks, 3.1% of patients receiving zilurgisertib developed new heterotopic ossification lesions compared to 16.7% in the placebo group, representing an 81% reduction.

Mirum and Incyte report positive phase 2 results for FOP treatment

Sun, 14 Jun 2026 16:35:17 -0400

At 24 weeks, 3.1% of patients receiving zilurgisertib developed new heterotopic ossification lesions compared to 16.7% in the placebo group, representing an 81% reduction.

Mirum and Incyte report positive phase 2 results for FOP treatment

Sun, 14 Jun 2026 16:35:17 -0400

At 24 weeks, 3.1% of patients receiving zilurgisertib developed new heterotopic ossification lesions compared to 16.7% in the placebo group, representing an 81% reduction.

Mirum and Incyte report positive phase 2 results for FOP treatment

Sun, 14 Jun 2026 16:35:17 -0400

At 24 weeks, 3.1% of patients receiving zilurgisertib developed new heterotopic ossification lesions compared to 16.7% in the placebo group, representing an 81% reduction.

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva